BERMUDA-BUSINESS
22.11.2022 14:38:42 CET | Business Wire | Press release
From November 17-19, a delegation from Bermuda travelled to Lake Como, Italy to promote Bermuda as a premier domicile for high-net-worth services to private client lawyers from all over the world
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221122005517/en/
Bermuda representatives (from left) Alec Anderson, Quadrant Advisors; Lorinda Gazzard, Butterfield; Keith Robinson, Carey Olsen; Randall Krebs, Harbour International Trust Company; Scott Pearman, Conyers; Craig W. MacIntyre, Conyers; David Hart, BDA; Andrea Jackson, BDA; Michael Neff, Butterfield; Kevin Dallas, Butterfield; Nir Sadeh, Butterfield; Jeffrey P. Elkinson, Conyers; Gina Pereira, Meritus Trust. (Photo: Business Wire)
Representing the BDA was CEO David Hart and independent board member, Andrea Jackson, while senior representatives from Butterfield, Carey Olsen, Conyers, Harbour International, Meritus Trust, and Quadrant Advisors were also in attendance.
David Hart said, “The BDA’s main purpose here at the International Private Client Forum, which is held in association with Butterfield, is to share the message of Bermuda's safety and stability as a blue-chip jurisdiction for attracting and welcoming foreign direct investment. There is a larger Bermuda delegation here beyond the BDA, including leading professionals in our legal, banking and trust communities, all of whom have substantial experience in advising high net worth individuals and families and are at the forefront of the private wealth industry.”
Michael Neff, Butterfield’s Managing Director of Bermuda and International Wealth, welcomed delegates to the three-day forum of panel discussions, roundtables and workshops. Carey Olsen Bermuda partner and head of the Bermuda disputes team, Keith Robinson, spoke on a panel session entitled 'Drafting Carefully: Planning Lessons Learned from Recent Cases' and Conyers director Scott Pearman joined a roundtable discussion entitled ‘Criminal Enforcement: Our Shifting Role’.
Bermuda’s attendance at what is referred to as the world’s preeminent gathering of private client lawyers builds on three major in-person high-net-worth services events that returned to Bermuda this summer, the first since 2019.
Along with Butterfield, the BDA co-sponsored a ‘Private Client Exchange Bermuda 2022’ event in June 28-29. This sold-out event brought about 50 of the world’s top lawyers to the St Regis Bermuda Resort.
As part of our commitment to Bermuda’s high net worth services industry, the BDA also sponsored two other in-person international trust and private investors events in June and July. These events not only brought global trust and legal leaders to the Island to discuss important hot topics and best practices but the immediate economic impact of the first two, including lodging, transportation, food and beverage, retail and recreation, was estimated at over half million dollars, and supported around 240 jobs.
If you would like to learn more about Bermuda’s high-net-worth services sector, contact Korrin Lightbourne, Senior Business Development Coordinator at info@bda.bm or +1 441 292 0632.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate, or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221122005517/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
Compass Pathways Announces FDA Granted NDA Rolling Review Request and Awarded Commissioner's National Priority Voucher24.4.2026 16:37:00 CEST | Press release
Compass is the most advanced company in classic psychedelics and has generated positive data from two ongoing large, well controlled Phase 3 clinical trials, designed to uphold the highest regulatory standardsFDA grants Compass NDA rolling submission and review request, based on Phase 3 dataCNPV awarded for COMP360, Compass’ proprietary formulation of synthetic psilocybin, for treatment-resistant depression (TRD)CNPV further accelerates momentum and Compass is confident and ready to deliver for patients Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the U.S. Food and Drug Administration (FDA) granted Compass NDA rolling review request and selected COMP360, Compass’ proprietary formulation of synthetic psilocybin, for the Commissioner's National Priority Voucher (CNPV) program for treatment-resistant depression (TRD). Companies selected for the voucher program will be en
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
